Indian Pharmaceuticals Say Antibiotic API Prices Could Increase By Half
This article was originally published in PharmAsia News
Indian drug makers say the active pharmaceutical ingredients for antibiotics could cost as much as 50 percent more as a result of a government anti-dumping response
You may also be interested in...
The Phase III FIDELIO trial of finerenone has been a success but analysts want to see some actual data before declaring it an unqualified one.
Gilead says remdesivir improved mortality and clinical recovery in COVID-19 patients, but the findings come from a retrospective analysis, not a traditional clinical trial.
Agency resuming domestic inspections with the help of a pandemic rating system to identify localities where inspections will be safest for investigators and plant workers. Another safety factor: all inspections will be pre-announced.